

Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.

Daniel Aaron Pollyea, Courtney Denton Dinardo, Stéphane de Botton, Eytan Stein, et al.

Conclusion: *In a high-risk, molecularly defined R/R AML patient population, IVO induced durable remissions and was well tolerated. Studies in previously untreated AML populations are ongoing.*

[J Clin Oncol 36, 2018 \(suppl; abstr 7000\)](#)

[SEE ALSO ARTICLE IN NEJM](#) (Courtney Denton Dinardo, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML)